Can Cabergoline shrink pituitary tumors and observe its efficacy

Cabergoline is a long-acting dopamine receptor agonist, mainly used to treat pituitary tumors caused by hyperprolactinemia (hyperprolactinemia). It activates pituitary gland dopamineD2 receptors and inhibits prolactin (PRL) secretion, thereby alleviating symptoms caused by elevated prolactin levels and also reducing the size of prolactinoma.

Clinical studies have shown that cabergoline can significantly reduce serum prolactin levels in most patients with prolactinoma. About 70%-80% of patients can recover their blood prolactin to the normal range after taking the medicine regularly for several weeks to several months, and symptoms such as menstrual disorders, galactorrhea, sexual dysfunction, etc. will be significantly improved. Long-term use of the drug can also maintain stable blood prolactin levels and reduce the risk of recurrence.

In terms of pituitary tumor volume, cabergoline also showed a good reduction effect. According to a number of clinical observations, after treatment for 3 to 6 months, most patients with small and medium-sized prolactinoma can reduce the size of their tumors by 30%-50%, and some patients can even shrink by 50%. The efficacy is closely related to the patient's initial tumor size, prolactin level and dose compliance. The smaller the tumor and the lower the initial prolactin level, the more significant the shrinkage effect.

Overall, cabergoline not only effectively reduces blood prolactin levels, but also has a considerable effect on reducing the size of prolactinoma. During use, patients should regularly monitor blood prolactin and imaging indicators as directed by their doctor, and adjust the dosage according to efficacy and tolerance. At the same time, for large pituitary tumors or aggressive tumors, combined surgery or radiation therapy may be needed to obtain the best therapeutic effect.

Reference materials:https://www.drugs.com/